Axsome Therapeutics AXSM 深 滬
已收盤 08-07 16:00:00 美东时间
212.74
+2.610
+1.24%
華盛通- 最 高214.39
- 今 開210.13
- 成交量 102.44万股
- 最 低 208.6051
- 昨 收 210.13
- 總市值 109.48亿
- 52周最高 260.19
- 市盈率 靜 --
- 換手率 1.99%
- 52周最低 109.40
- 委 比 -13.61%
- 總股本 5145.98万
- 歷史最高 260.19
- 量 比 1.56
- 振 幅 2.75%
- 歷史最低 1.94
- 每 手 1
- 風險率 43.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $306
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $310 to $306.
08-01 01:37
Axsome Advances AXS-14 Fibromyalgia Trial With New Long-Term Safety Update
Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical ...
07-25 00:36
Axsome’s CLARITY Trial Targets Sleepy Depression: What Investors Should Watch
Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical ...
07-25 00:35
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
ClearBridge Small-Cap Growth Strategy adds new positions, exits others
ClearBridge Small-Cap Growth Strategy returned 21% in Q2 2026, underperforming the Russell 2000 Growth Index, which gained 26% during the same period. During Q2 2026, the strategy initiated 13 new pos...
07-20 22:08
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Nvidia (NVDA) and Lam Research (LRCX) are among the largest names on Oppenheimer’s latest “best of the best” momentum screen. Oppenheimer’s technical analysis team said the list provides technical col...
07-20 03:10
Axsome gains as narcolepsy therapy undergoes FDA review
Shares of Axsome Therapeutics were up in the premarket on Wednesday after the company announced that the U.S. FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy fo...
07-15 19:55
Axsome Therapeutics Says FDA Accepts NDA For AXS-12 For Treatment Of Cataplexy In Narcolepsy; PDUFA Target Action Date Set May 1, 2027
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-12 (reboxetine)...
07-15 19:03
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
FDA has accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The agency also stated it does not plan to hold an advisory committee meeting for the application. AXS-12 is an orphan drug candidate designed to modulate noradrenergic and dopaminergic signaling to maintain muscle tone and promote wakefulness. Narcolepsy is a debilitating neuro...
07-15 11:00
